 Home > Active Ingredient News > Blood System > Blood: Efficacy and safety of Ivosidenib or Enasidenib combined with intensive chemotherapy for newly diagnosed AML adult patients

Blood: Efficacy and safety of Ivosidenib or Enasidenib combined with intensive chemotherapy for newly diagnosed AML adult patients

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

clarithromycin 500 mg

rutin 500 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Intensive induction chemotherapy containing cytarabine and anthracyclines is still the most effective treatment for newly diagnosed adult patients with acute myeloid leukemia (AML).

Isocitrate dehydrogenase (IDH) 1 or 2 gene mutations are seen in about 20% of AML patients .

Isocitrate dehydrogenase (IDH) 1 or 2 gene mutations are seen in about 20% of AML patients

Ivosidenib (AG-120) and Enasidenib (AG-221) are targeted oral small molecule inhibitors of mutant isocitrate dehydrogenase (mIDH1) 1 and 2 enzymes, respectively .

Ivosidenib (AG-120) and Enasidenib (AG-221) are targeted oral small molecule inhibitors of mutant isocitrate dehydrogenase (mIDH1) 1 and 2, respectively.

Ivosidenib 500 mg (1/day) and Enasidenib 100 mg (1/day) are well tolerated under the conditions of the study, and their safety is consistent with that of single induction and consolidation chemotherapy

Overall survival rate

In patients receiving Ivosidenib+ intensive chemotherapy, the frequency and grade of QT interval prolongation were similar to those observed during Ivosidenib monotherapy .

In patients receiving Ivosidenib+ intensive chemotherapy, the frequency and grade of QT interval prolongation are similar to those observed during Ivosidenib monotherapy

Basic mutation profile and best overall clinical response

In patients receiving Ivosidenib (n=60) or Enasidenib (n=91), the complete remission rate after induction was 55% and 47%, respectively, with CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/ CRp) rates were 72% and 63%, respectively .

Among the patients with the best overall CR/CRi/CRp response, 16/41 (39%) patients in the Ivosidenib group had IDH1 mutation clearance, while 15/64 (23%) in the Enasidenib group had IDH2 mutations Removal (PCR); In addition, 16/20 (80%) and 10/16 (63%) patients had detectable residual disease turned negative (multi-parameter loss cytometry).

In conclusion, Ivosidenib or Enasidenib combined with intensive chemotherapy can improve the prognosis of newly diagnosed adult patients with mIDH1/2 AML.

Original source:

Eytan M.

org/10.
1182/blood.
2020007233" target="_blank" rel="noopener">Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.